Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.47 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.39 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13849581 | 0.88 | SLC2A1 (0.46) | FAAHALDH1A1 | |
| SCHEMBL13849585 | 0.85 | ROCK1 (0.40) | FAAHKDM4EALDH1A1LMNALTB4R | |
| SCHEMBL28467850 | 0.80 | CHRNB2 (0.56) | FAAHKDM4EALDH1A1LMNALTB4R | |
| SCHEMBL4135891 | 0.80 | FAAH (0.43) | FAAHSIGMAR1KDM4EALDH1A1LMNA | |
| SCHEMBL25495948 | 0.77 | KDM4E (0.56) | FAAHKDM4EALDH1A1LMNA | |
| SCHEMBL4142373 | 0.76 | PLA2G4B (0.46) | FAAHKDM4EALDH1A1LMNALTB4R | |
| Hydrochloric Acid SCHEMBL4131422 | 0.75 | PLA2G4B (0.45) | FAAHKDM4EALDH1A1LMNALTB4R | |
| SCHEMBL13850444 | 0.74 | SLC2A1 (0.45) | FAAH | |
| SCHEMBL15743158 | 0.74 | CHRM4 (0.46) | RAB9ASIGMAR1ALDH1A1LMNAPOLB | |
| SCHEMBL2768717 | 0.73 | SLC7A5 (0.48) | SIGMAR1KDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118263-A1 | Novel Adenine Compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
| EP-1939202-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118263-A1 | Novel Adenine Compound | ADORA1, ADORA2A, ADORA3 | FAAH 2884/4885CCR5 1830/4885NPC1 1352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.